Cargando…

Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose

PURPOSE: The aim of this study was to ascertain whether the absolute bioavailability of oral imatinib (Glivec®) during steady state plasma pharmacokinetics in cancer patients could be determined through a concomitant intravenous administration of a single 100 μg microdose of deuterium labeled imatin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roosendaal, Jeroen, Groenland, Stefanie L., Rosing, Hilde, Lucas, Luc, Venekamp, Nikkie, Nuijen, Bastiaan, Huitema, Alwin D. R., Beijnen, Jos H., Steeghs, Neeltje
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351863/ https://www.ncbi.nlm.nih.gov/pubmed/32430518 http://dx.doi.org/10.1007/s00228-020-02888-y

Ejemplares similares

Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in Oncology
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Phase I pharmacological study of continuous chronomodulated capecitabine treatment
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients
por: Groenland, Stefanie L., et al.
Publicado: (2020)

Toxicological analysis of azide and cyanide for azide intoxications using gas chromatography
por: Bruin, Maaike A. C., et al.
Publicado: (2020)

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?
por: Embaby, Alaa, et al.
Publicado: (2022)

A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens
por: van der Heijden, Lisa, et al.
Publicado: (2022)

Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
por: Groenland, Stefanie L., et al.
Publicado: (2018)

Mass balance and metabolite profiling of (14)C-guadecitabine in patients with advanced cancer
por: Roosendaal, Jeroen, et al.
Publicado: (2019)

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar()
por: Sawicki, Emilia, et al.
Publicado: (2016)

The influence of body mass index on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in women with early-stage breast cancer
por: Lin, Lishi, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs
por: Molenaar-Kuijsten, Laura, et al.
Publicado: (2021)

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
por: Boosman, René J., et al.
Publicado: (2022)

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
por: Verheijen, Remy B., et al.
Publicado: (2017)

Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS
por: de Jong, Karen A.M., et al.
Publicado: (2021)

Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies
por: Hedenström, Per, et al.
Publicado: (2017)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

The stable isotope method for determining absolute bioavailability
por: Atkinson, Arthur J.
Publicado: (2017)

The pharmacogenetics of imatinib
por: Dulucq, Stéphanie, et al.
Publicado: (2010)

Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies
por: van Eijk, Maarten, et al.
Publicado: (2022)

Primary imatinib failure rescued by dasatinib and maintained by reintroduction of imatinib
por: Kumar, Rajiv, et al.
Publicado: (2017)

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
por: Verheijen, Remy B., et al.
Publicado: (2017)

Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors
por: Chi, Ping, et al.
Publicado: (2022)

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
por: Keizer, Ron J, et al.
Publicado: (2015)

Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
por: Mohammadi, Mahmoud, et al.
Publicado: (2023)

Exploiting the promiscuity of imatinib
por: Lee, Shun J, et al.
Publicado: (2009)

Imatinib-induced pancreatitis
por: Varma, Mahesh R., et al.
Publicado: (2010)

Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)

Imatinib Use in Pregnancy
por: Webb, Michael J, et al.
Publicado: (2012)

Imatinib-Induced Psoriasis
por: Atalay, Figen, et al.
Publicado: (2013)

The Side Effects of Imatinib
por: Uzer, Elmas, et al.
Publicado: (2013)

Imatinib-induced Gynecomastia
por: Gupta, Pragya, et al.
Publicado: (2019)

The Effect of Apigenin on Pharmacokinetics of Imatinib and Its Metabolite N-Desmethyl Imatinib in Rats
por: Liu, Xian-yun, et al.
Publicado: (2013)

Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data
por: den Hollander, Dide, et al.
Publicado: (2022)

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
por: Joensuu, Heikki, et al.
Publicado: (2023)

A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: A case study on cold‐labeled venetoclax, from chemistry to the clinic
por: Alaarg, Amr, et al.
Publicado: (2021)

Giving imatinib a hand
por: Maxmen, Amy
Publicado: (2008)

IMATINIB INDUCED LICHEN PLANUS
por: Sudha, R, et al.
Publicado: (2011)

Correction: Exploiting the promiscuity of imatinib
por: Lee, Shun J, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_g6f510bli19l4pi3cnk62q2gtk